Runben Biotechnology Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	109.39	106.59	243.83	368.21	206.19	39.53
Short-Term Investments	-	77.95	1,340	-	-	-
Trading Asset Securities	1,021	1,249	19	8.24	56.24	42.17
Cash & Short-Term Investments	1,131	1,434	1,603	376.45	262.43	81.7
Cash Growth	185.34%	-10.57%	325.85%	43.45%	221.20%	130.74%
Accounts Receivable	32.24	13.59	4.82	1.19	2.34	2.78
Other Receivables	5.42	4.62	2.32	6	9.8	5.73
Receivables	37.66	18.22	7.14	7.2	12.15	8.51
Inventory	135	118.57	92.91	102.71	56.9	45.22
Other Current Assets	316.61	24.43	13.16	23.68	12.89	6.38
Total Current Assets	1,620	1,595	1,716	510.04	344.36	141.82
Property, Plant & Equipment	292.79	267.57	260.42	277.56	207.67	108.73
Other Intangible Assets	87.85	54.54	18.76	19.36	19.88	20.54
Long-Term Deferred Tax Assets	46.2	44.23	20.82	14.8	5.66	2.39
Long-Term Deferred Charges	1.56	1.26	1.41	-	-	-
Other Long-Term Assets	258.04	256.9	1.13	3.65	68.77	2.99
Total Assets	2,307	2,219	2,019	825.42	646.34	276.47
Accounts Payable	84.8	53.8	40.15	36.99	46.37	13.27
Accrued Expenses	9.7	32.16	26.21	24.43	11.41	5.98
Current Portion of Leases	1.4	1.37	1.95	2.51	2.4	-
Current Income Taxes Payable	25.51	26.29	15.47	18.28	5.29	0.63
Current Unearned Revenue	2.96	13.37	5.97	4.5	4.2	3.44
Other Current Liabilities	5.14	10.21	5.36	9.89	5.84	0.92
Total Current Liabilities	129.51	137.19	95.12	96.6	75.52	24.23
Long-Term Leases	0.36	1.42	2.04	5.39	7.91	-
Long-Term Unearned Revenue	3.96	0.01	0.01	0.27	1.13	2.05
Long-Term Deferred Tax Liabilities	0.23	0.27	0.44	0.57	0.14	0.05
Total Liabilities	134.06	138.88	97.61	102.83	84.69	26.33
Common Stock	404.59	404.59	404.59	343.9	343.9	103.07
Additional Paid-In Capital	1,015	1,015	1,015	102.59	101.69	117.28
Retained Earnings	752.75	660.67	502.12	276.09	116.05	29.79
Shareholders' Equity	2,173	2,080	1,921	722.59	561.65	250.14
Total Liabilities & Equity	2,307	2,219	2,019	825.42	646.34	276.47
Total Debt	1.76	2.78	4	7.91	10.31	-
Net Cash (Debt)	1,129	1,431	1,599	368.54	252.12	81.7
Net Cash Growth	187.16%	-10.52%	333.90%	46.18%	208.59%	130.74%
Net Cash Per Share	2.81	3.53	4.53	1.08	0.75	0.27
Filing Date Shares Outstanding	404.59	404.59	404.59	404.59	343.9	305.52
Total Common Shares Outstanding	404.59	404.59	404.59	343.9	343.9	305.52
Working Capital	1,491	1,458	1,621	413.44	268.84	117.59
Book Value Per Share	5.37	5.14	4.75	2.10	1.63	0.82
Tangible Book Value	2,085	2,026	1,903	703.22	541.76	229.6
Tangible Book Value Per Share	5.15	5.01	4.70	2.04	1.58	0.75
Buildings	-	231.94	232.54	231.65	163.47	43.21
Machinery	-	96.7	87.77	79.06	57.22	29.25
Construction In Progress	-	18.07	1.82	5.76	7.17	59.01

Source: S&P Global Market Intelligence. Standard template. Financial Sources.